TL;DR
- Negotiations are moving from talking points to real legislative text.
- The biggest issue is the cap per year per company. Ernst has suggested this decision go to the Agency level, and latest feedback from Markey is text that effectively makes the compromise meaningless.
- There is meaningful convergence on Phase III transition and modernization and a new “strategic breakthrough” pathway would enable Phase II awards up to $30M with 100% matching funds and faster award timelines, for certain agency, company, and product combinations.
- Research security and foreign risk screening are tightened and clarified, including list-based triggers and expanded due diligence categories.
What changed, and why it feels different this time
Over the past week, the reauthorization conversation started to look more like a negotiation between two drafts of the same bill, rather than two sides talking past each other. Legislative analysis that we conducted early the week of JPM (Jan 16th ) highlights that the posture is still serious and incomplete, but the bargaining is now anchored in text that can be compared line by line. That evolution matters, because once legislative counsel language is on the table, the remaining gaps are cap per company and permanent law versus a 3-year bridge, among others.
Capping number of applications per year, per company
One of the most immediately practical changes is the proposal cap requirement. The cap would not affect 99+% of the companies in the program. But it would limit the number of applications submitted per year per company and would affect firms that use SBIRs as the end (“SBIR Mills”), not a mechanism for developing products to get them in the marketplace. The Ernst draft would require the head of each agency with an SBIR or STTR program to set a limit on the maximum number of Phase I or Phase II proposals a small business (including affiliates) may submit to that agency in a fiscal year. That is not a small operational tweak. It would force certain teams to be more selective, invest earlier in fit assessment, and treat each submission slot like a scarce asset. We believe this is healthy and will focus efforts rather than divert funds away from real impact.
Where both sides are converging: Phase III is the destination
If there is one take-away, it is this: Phase III is no longer treated as a side quest. It is treated as the entire point of the SBIR program. The Ernst draft adds a Phase III Award Education section that would require training for contracting officers and the acquisition workforce, and it pairs that with Phase III “process plumbing” such as model contracts, standardized clauses, and simplified procedures. In practice, this is exactly the kind of change that can turn Phase III from an exception into muscle memory across agencies.
Strategic breakthrough awards: a bigger lane with clearer gates
The Ernst counterproposal introduces a Phase II “strategic breakthrough” pathway that uses up to 0.75% of an eligible agency’s extramural budget for awards up to $30 million, with a total period of performance up to 48 months. To qualify, a company must have at least one prior Phase II award and demonstrate at least 100% matching funds from new private capital, new non-SBIR government funding, or a combination. For Department of Defense use, the bar is higher: the product or technology would need a commitment for inclusion in a program objective memorandum from a program acquisition executive or higher, and it must address high-priority operational needs. Speed is a new hallmark: the draft requires agencies to complete contract awards using strategic breakthrough funds within 90 days after receiving a proposal, and it directs agencies to implement streamlined application processes.
Research security: clearer triggers, broader due diligence, and a notification pathway
Research security remains the hottest topic in the negotiations. The Ernst draft would require agencies to evaluate whether an applicant presents a risk to national security for any reason, including through due diligence, disclosures, and coordination with intelligence and law enforcement. It also defines “foreign risk” using specific government lists, and it expands the due diligence “security risks” assessment to cover cybersecurity practices, patent analysis, employee analysis, foreign ownership and obligations, research relationships, investment relationships, licensing agreements and joint ventures, and other business relationships tied to a foreign country of concern. Importantly for applicants, the draft includes a process for notifying a small business when an application is denied on these grounds, including identifying the criteria that formed the basis for the determination, while allowing agencies to protect national security, and clarifies that denial in one cycle does not automatically prohibit eligibility in a later cycle.
Technical and business assistance: more flexible, more modern, more aligned to commercialization
On Technical and Business Assistance (TABA), the direction is toward flexibility and modernization, including coverage for cybersecurity assistance and screening for potential foreign involvement in development or commercialization activities. For companies, the takeaway is simple: the policy conversation continues to help awardees de-risk commercialization and compliance, not to fund just R&D.
Be prepared: what to do now while Congress negotiates
Reauthorization debates can feel like calendar watching. The better posture is capability building. When the reauthorization happens, prepared teams will have the advantage. Here is a practical readiness checklist:
- Be ready to submit for the next normal deadline. It is most likely things will move quickly.
- Map your foreign risk exposure and tighten your documentation, including ownership, affiliations, research relationships, and cybersecurity posture.
- Prepare for proposal caps by upgrading your internal opportunity triage, scoring, and “go/no go” discipline.
- If you are a defense-facing company, start aligning early with acquisition stakeholders and evidence of demand (including POM alignment where relevant).
- Build a Phase III transition plan for every serious Phase II proposal, including who the end user is and the contracting pathway you intend to use.
- Treat matching funds strategy as a capability, not a last-minute scramble, especially if you could be a candidate for strategic breakthrough awards.
The tone from Washington is not “pause,” it is “be ready.” The community that wins the next cycle will be the one that treats this period as preparation time, not downtime.
Need help securing significant funding? If you have questions about how these updates affect your strategy, or want support preparing for finding new opportunities, contact us. Together, we will continue pushing innovation forward.
text: (650) 885-9872
email: greatscience@grantengine.com
Website: grantengine.com